Julie Rathbun
Investor Relations Contact at ATHIRA PHARMA, INC.
Profile
Julie Rathbun is the founder and president of Rathbun Communications, Inc. founded in 2004.
She is currently the Head of Public and Investor Relations at Athira Pharma, Inc. Ms. Rathbun has previously worked as the Head of Investor Relations at Sarepta Therapeutics, Inc., Media Relations Contact at Immune Design Corp., and Media Contact at Neoleukin Therapeutics, Inc. Ms. Rathbun has an undergraduate degree from Western Washington University.
Julie Rathbun active positions
| Companies | Position | Start |
|---|---|---|
| ATHIRA PHARMA, INC. | Investor Relations Contact | - |
| Rathbun Communications, Inc. | Founder | 01/01/2004 |
Former positions of Julie Rathbun
| Companies | Position | End |
|---|---|---|
| IMMUNE DESIGN CORP | Public Communications Contact | 02/04/2019 |
| NEUROGENE INC. | Public Communications Contact | - |
| SAREPTA THERAPEUTICS, INC. | Public Communications Contact | - |
Training of Julie Rathbun
| Western Washington University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
| Rathbun Communications, Inc. |
- Stock Market
- Insiders
- Julie Rathbun
